Xencor (XNCR)
(Delayed Data from NSDQ)
$19.98 USD
+0.75 (3.90%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $19.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Brokerage Reports
0 items in cart
Xencor, Inc. [XNCR]
Reports for Purchase
Showing records 121 - 140 ( 216 total )
Company: Xencor, Inc.
Industry: Medical - Drugs
Looking to ASH Update for First Bispecific Read, IgG4-RD Ph 3 Begins Early ''19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
CORRECTED: ASH 2018 Abstract Roundup and Schedule for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
No Harm, No Foul: A Miss in Lupus, Never Part of our Valuation
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
HEALTHCARE - 2018 Wedbush PacGrow Healthcare Conference: Day 2 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Xencor, Inc.
Industry: Medical - Drugs
Data Timelines on Track, with Potential for Upside Surprise Later this Year
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Xencor, Inc.
Industry: Medical - Drugs
Partnered and Wholly-Owned Assets Inching Forward
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
Company: Xencor, Inc.
Industry: Medical - Drugs
Biotechnology - ASCO Abstract Titles Released
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Xencor, Inc.
Industry: Medical - Drugs
ALXN1210 Clears a Ph 3, while Accelerated Filing Strategy laid out for MOR208
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
Company: Xencor, Inc.
Industry: Medical - Drugs
5871 Ph 3 in 2H, Bispecifics and Partnered Programs Progressing, Adding 1210
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
Company: Xencor, Inc.
Industry: Medical - Drugs
Updates at ASH for Partnered Programs, Overlooked Value Drivers for XNCR
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
Company: Xencor, Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D